Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) finished Wednesday with an addition of $0.85 to close at $106.12, an upside of 0.81 percent. An average of 1,815,300 shares of common stock have been traded in the last five days. There was a gain of $2.01 in the past week, and it reached a new high 20 times over the past 12 months. The last 20 days have seen an average of 1,485,355 shares traded, while the 50-day average volume stands at 1,632,748.
HZNP stock has increased by 5.88% in the last month. The company shares reached their 1-month lowest point of $98.80 on 08/03/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $57.84 and a high of $113.83 in 52 weeks. It has reached a new high 1 time so far this year and lost -6.75% or -$7.68 in price. In spite of this, the price is down -6.77% from the 52-week high.
Insider Transactions
HZNP stock investors should be aware that Horizon Therapeutics Public Limited Company (HZNP) stock had its last reported insider trading activity 219 days ago on Jan 17. In this transaction, the insider spent $3,066,323. EVP, Chief Financial Officer, Cox Aaron, disposed of 36,148 shares at a price of $113.17 on Jan 13. The insider now owns more than $4,090,847 worth of shares. Prior to that, EVP and Chief Medical Officer SHERMAN JEFFREY W went on to Sale 3,368 shares at $113.10 each on Jan 11. An amount of $380,921 was transacted.
Valuation Metrics
Horizon Therapeutics Public Limited Company (HZNP) has a trailing price-to-earnings (P/E) ratio of 56.72. The stock’s beta is 1.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.66, the price-to-book (PB) ratio at 4.57, and the price-to-cash flow ratio at 25.34.
Financial Health
The quick ratio of Horizon Therapeutics Public Limited Company for the three months ended June 29 was 4.10, and the current ratio was 4.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.48 and a total debt to equity ratio of 0.48 for the quarter ending June 29. Horizon Therapeutics Public Limited Company’s EBITDA margin for the year ending June 29 is 30.09%, while its operating margin for the same period stands at 14.10%. Its gross profit as reported stood at $2.71 billion compared to revenue of $3.63 billion.
Earnings Surprise
For the three-month period that ended June 29, Horizon Therapeutics Public Limited Company had $2.54 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $127.07 million in the quarter, while revenues of $54.68 million were grew 52.02%. The analyst consensus anticipated Horizon Therapeutics Public Limited Company’s latest quarter earnings to come in at $1.03 per share, but it turned out to be $1.2, a 16.50% surprise. For the quarter, EBITDA amounted to $240.43 million. Shareholders own equity worth $229.0 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Horizon Therapeutics Public Limited Company (HZNP) price momentum. RSI 9-day as of the close on 23 August was 78.59%, suggesting the stock is Overbought, with historical volatility in this time frame at 7.33%.
As of today, HZNP’s price is $104.80 +1.93% or $2.01 from its 5-day moving average. HZNP is currently trading +6.20% higher than its 20-day SMA and -2.86% lower than its 100-day SMA. However, the stock’s current price level is +6.31% above the SMA50 and +45.51% above the SMA200.
The stochastic %K and %D were 92.50% and 88.37%, respectively, and the average true range (ATR) was 1.06. With the 14-day stochastic at 94.43% and the average true range at 1.06, the RSI (14) stands at 71.40%. The stock has reached 0.96 on the 9-day MACD Oscillator while the 14-day reading was at 1.52.
Analyst Ratings
H.C. Wainwright launched coverage on Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) in its analyst report released on November 01, 2022. The firm assigned the stock a Neutral rating. The consensus rating for Horizon Therapeutics Public Limited Company (HZNP) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HZNP, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is HZNP’s price target for the next 12 months?
Analysts predict a range of price targets between $116.50 and $116.50, with a median target of $116.50. Taking a look at these predictions, the average price target given by analysts for Horizon Therapeutics Public Limited Company (HZNP) stock is $116.50.
